2021 Fiscal Year Final Research Report
Functional analysis of CD109 in tumor progression using osteosarcoma cells and tissue
| Project/Area Number |
19K07503
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 49030:Experimental pathology-related
|
|---|
| Research Institution | Nagoya University |
|---|
Principal Investigator |
Mii Shinji 名古屋大学, 医学系研究科, 准教授 (80646505)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高橋 雅英 藤田医科大学, その他部局等, 教授 (40183446)
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | CD109 / 骨肉腫 / TGF-β / BMP |
|---|
| Outline of Final Research Achievements |
In this study, we investigated the role of CD109 using osteosarcoma cell lines and human osteosarcoma tissue. We performed immunohistochemical analysis on human osteosarcoma tissue and found that patients with CD109-high osteosarcoma had a significantly worse prognosis than those with CD109-low one.
Although no significant difference was found in TGF-β1 signaling between CD109-knockdown osteosarcoma cells and control cells, we observed that CD109 suppressed SMAD1/5/9 phosphorylation by BMP-2, which is one of the member of TGF-β superfamily.
These results suggest that CD109 is involved in the exacerbation of osteosarcoma via not TGF-β but BMP singlaing.
|
| Free Research Field |
実験病理学
|
| Academic Significance and Societal Importance of the Research Achievements |
近年，多くのがんで効果的な治療法が登場しているにも関わらず，難治性の希少がんである骨肉腫においては依然として新規治療法の開発が進んでいない．本研究では，CD109の発現が高い骨肉腫症例が，CD109の発現が低い症例に比べて有意に予後不良であり，その原因の1つがCD109による影響であることを示す成果が得られており，CD109を標的とした骨肉腫の新規治療法の開発につながる可能性がある．
|
